Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings
Open Access
- 1 January 2006
- journal article
- other
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (1) , 101-104
- https://doi.org/10.1136/ard.2004.034348
Abstract
Background: The process of bone remodelling is disturbed in the development of osteoporosis. Objective: To investigate if proteins in osteoporotic bone are modified by advanced glycation end products (AGEs), and whether these alterations are related to measures of bone remodelling based on histomorphometric findings. Methods: Bone specimens taken from the iliac crest by bone biopsy of eight osteoporotic patients were investigated by histomorphometry and by immunohistochemical staining with the AGEs imidazolone and Nε-carboxymethyllysine. Results: Both AGEs were found in all bone specimens. The intensity of staining correlated with patient age. The percentage of bone surface covered with osteoblasts showed a significantly negative correlation with the staining intensity of both AGEs. Conclusions: It is known that AGEs can regulate proliferation and differentiation of osteoblastic cells and that AGE-specific binding sites are present in cultured osteoblast-like cells. Moreover, AGE induced biological effects in these cells might be mediated by RAGE (receptor of AGE) or by other AGE receptors in different stages of osteoblast development. The inverse relation between AGE staining intensity and the percentage of bone surface covered with osteoblasts in the trabecular bone may provide evidence that AGE modification of bone proteins disturbs bone remodelling.Keywords
This publication has 15 references indexed in Scilit:
- Advanced glycation end-products pentosidine and N -carboxymethyllysine are elevated in serum of patients with osteoporosisRheumatology, 2003
- Genetic regulation of osteoclast development and functionNature Reviews Genetics, 2003
- Maillard reaction products in tissue proteins: New products and new perspectivesAmino Acids, 2003
- Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK)Molecular and Cellular Biochemistry, 2003
- The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responsesJournal of Clinical Investigation, 2001
- The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responsesJournal of Clinical Investigation, 2001
- Protein Glycation, Diabetes, and AgingRecent Progress in Hormone Research, 2001
- Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.Journal of Clinical Investigation, 1997
- Role of nonenzymatic glycosylation of type I collagen in diabetic osteopeniaJournal of Bone and Mineral Research, 1996
- Quantum concept of bone remodeling and turnover: Implications for the pathogenesis of osteoporosisCalcified Tissue International, 1979